Centiva Capital, LP Halozyme Therapeutics, Inc. Transaction History

Centiva Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$37.81 - $52.4 $335,904 - $465,521	8,884 New	8,884 $465,000
Q2 2023 Aug 14, 2023	BUY	$30.28 - $38.74 $178,712 - $228,643	5,902 New	5,902 $212,000
Q4 2022 Feb 14, 2023	BUY	$40.06 - $59.44 $277,575 - $411,859	6,929 New	6,929 $394,000
Q3 2021 Nov 15, 2021	SELL	$38.47 - $46.42 $334,727 - $403,900	-8,701 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$38.84 - $51.31 $337,946 - $446,448	8,701 New	8,701 $395,000
Q4 2019 Feb 14, 2020	SELL	$14.93 - $19.53 $178,114 - $232,992	-11,930 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$15.2 - $17.69 $181,336 - $211,041	11,930 New	11,930 $185,000

543

125M

294K

180K

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $6.62B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.